Back to Astrocytoma, Idh-Mutant, Grade 2

Astrocytoma, Idh-Mutant, Grade 2 — Clinical Trials

MONDO:09569943 active·2 recruitingLast updated: Mar 19, 2026, 11:05 PM

Trial Landscape

Astrocytoma, Idh-Mutant, Grade 2 has an emerging clinical trial program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment3

Procedure2

1 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 3

Sponsor Types

NIH2Industry1

Top Sponsors

Nuvation Bio Inc.

Trial Locations

United States3 trials

Australia1 trial

China1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

3 Trials

Phase 3Recruiting

NCT05303519

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Sponsor:Nuvation Bio Inc.

United StatesStarted: Jun 2023Est. completion: Dec 2030Updated: Mar 2026

Phase 1Recruiting

NCT06860594

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2025Est. completion: Jun 2027Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT03528642

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2019Est. completion: May 2026Updated: Mar 2026

Stay informed about clinical trials for Astrocytoma, Idh-Mutant, Grade 2.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 19, 2026 at 11:05 PM